Plozasiran Injection

Phase 3

Arrowhead Pharmaceuticals

Plozasiran Injection is one of 46 therapeutic programs targeting Hypertriglyceridemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HypertriglyceridemiaActive, not recruiting

HypertriglyceridemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

63 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Selzentry

Cipro

Lopid

Lovaza

3 5

Topamax

Zocor

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 8

Zetia

Statin

1 10

EVKEEZA

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Hypertriglyceridemia

NCT06347133

Clinical

Trials by Indication[1]

Hypertriglyceridemia1 trial

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia

Active, not recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT06347133·1,456 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Plozasiran Injection. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Plozasiran Injection. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Arrowhead Pharmaceuticals

Plozasiran Injection

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Hypertriglyceridemia1 trial

References

Drug Info

Quick Facts

Related News